Abstract. Somatostatin analogues such as octreotide are used to treat active acromegalic patients by reducing serum growth hormone (GH) levels. However, the acute effect of octreotide on GH secretion differs among patients. To elucidate factors influencing the acute effect of octreotide, we collected data from 56 patients with somatotroph adenoma from two institutions. We analyzed the correlation of the following factors with the acute effect of octreotide: immunohistochemical staining of somatostatin receptor subtype 2A (SSTR 2A), presence of gsp mutation, proliferative potentials analyzed by Ki-67 staining index (SI). We found that the acute effect of octreotide significantly correlated with two factors: Ki-67 SI and the plasma membrane-dominant staining pattern of SSTR 2A. Monovariate analysis revealed a statistically significant inverse relation of Ki-67 SI with the reduction of GH by octreotide. We assessed the contribution of each factor on the acute effect of octreotide by multivariate analysis. Significant multiple regression was confirmed with p value of 0.003. Post-test revealed that the plasma membrane-dominant staining pattern of SSTR 2A was significantly related to the reduction of GH by octreotide. These results show that the acute effect of octreotide is positively related to SSTR 2A staining on the plasma membrane.
TRANSSPHENOIDAL surgery is the first-line therapy for acromegaly. However, at least one-third of the patients with active somatotroph adenoma are not cured by surgery alone. Additional medical or radiological therapy has been used for postoperative patients who do not achieve remission. Somatostatin analogues including octreotide are applied to active acromegalic patients in order to normalize serum growth hormone (GH) secretion and insulin-like growth factor (IGF)-1 levels. However, the acute effect of octreotide on GH secretion differs among patients.
There are several factors known to influence the acute effect of octreotide on GH secretion. First, immunostaining of somatostatin receptor on the plasma membrane influences the outcome of the octreotide treatment [1] [2] [3] [4] . Secondly, tumors with the gsp mutation [5] [6] [7] display a better sensitivity to somatostatin, although some studies report the reverse result. Gsp mutation that is present in about 40% of somatotrophs adenomas could be a marker of the susceptibility of the tumor to octreotide [8, 9] . Meanwhile, the proliferative potential of the tumor is an important feature influencing the biological activity of the adenoma and may influence the acute effect of octreotide. Ki-67 immunostaining is an established method to assess the proliferative potential. However, the contribution of the proliferative potential on the acute effect of octreotide and the mutual relationship among these factors have not been evaluated.
In this study, we evaluated the contribution and mutual relationship of factors that may influence the acute effect of octreotide on GH secretion: Ki-67 staining index (SI), immunohistochemical staining of somatostatin receptor subtype 2A (SSTR 2A), and gsp mutation in a series of somatotroph adenomas. We also analyzed whether these three factors are related to other endocrinological data (basal GH, IGF-1, and responses of GH to bromocriptine and growth hormone releasing hormone (GHRH)) in our series.
Case Materials and Methods
Case materials and endocrinological findings (Table 1) An unselected series of 56 acromegalic patients (27 males and 29 females) with pituitary somatotroph adenoma treated in Teikyo University Chiba Medical Center and Nippon Medical School was employed. The institutional review board approved this clinical study, and written informed consent was obtained from the patients to use their endocrinological and pathological data. The age of the patients ranged from 22 to 67 years, with a mean age of 47.0 years (standard deviation (SD): 12.6).
Basal levels of serum GH (normal range: <0.42 ng/ ml for men, 0.66-3.68 ng/ml for women) ranged from 1.67 to 593 ng/ml. Basal levels of serum IGF-1 ranged from 210 to 1600 ng/ml. The percentage ratios of nadir GH to basal GH by octreotide loading test, by oral administration of 2.5 mg bromocriptine, and percentage ratios of peak GH to basal GH by 100 μg GHRH provocation tests were calculated. Serum GH was measured at 0, 1, 2, 4, 8, 12, 24 hr after subcutaneous injection of 100 μg octreotide, at 0, 1, 2, 4, 8, 12, 24 hr after oral administration of 2.5 mg bromocriptine, and at 0, 15, 30, 60, 90, 120 min after intravenous administration of 100 μg GHRH. These loading tests were examined preoperatively, at which time none of the patients received preoperative medical treatment using somatostatin analogue.
Histopathological examination
Paraffin sections were used for hematoxylin-eosin staining and immunohistochemical staining. They were deparaffinized and the endogenous peroxidase was inactivated with 0.3% H 2 O 2 in methanol. They were immunostained by an indirect peroxidase method with an antibody against human GH (rabbit, polyclonal, 1:400 diluted in 0.01 M phosphate buffered saline, pH 7.4 (PBS), DAKO, Carpinteria, CA, U.S.A.), to confirm that the adenomas were somatotrophic.
Immunohistochemical studies of Ki-67 staining index (SI)
Following blockage of the endogenous peroxidase activity with 0.3% H 2 O 2 in methanol, the Ki-67 antigen was retrieved with microwave irradiation for 30 min (10 times for 3 min). Paraffin sections were immunostained with an anti-Ki-67 monoclonal antibody, MIB-1 (mouse, DAKO, Carpinteria, CA, U.S.A.), at room temperature for 1 hr. The biotinylated antibody against mouse immunoglobulin (IgG) (goat, DAKO, Carpinteria, CA, U.S.A.) was applied as a secondary antibody for 30 min. Immunoreactions were followed by streptavidin and biotin complex (ABC) labeled with horseradish peroxidase using Vectastain ABC kit (Vector Laboratories Inc., Burlingame, CA, U.S.A.) for 30 min, and developed with freshly prepared 3,3'-diaminobendizine tetrahydrochloride (DAB) dissolved in 0.05 M Tris-HCl pH 7.6 and 0.017% H 2 O 2 for 7 min. Negative control studies included substituting normal serum for the primary antibody. The entire tissue sections were examined under high power magnification (× 400). The number of cells stained positively with MIB-1 and the total number of tumor cells were counted in several representative fields containing more than 1,000 cells in total. Their ratio was expressed as Ki-67 SI (%). Ki-67 SI was counted by two pathologists (K.Y. & Y.I.) who were blind to the endocrinological data of patients and the mean data of the two pathologists were used.
Immunohistochemical studies of somatostatin receptor 2A (SSTR 2A)
After paraffin sections were deparaffinized and the endogenous peroxidase was inactivated with 0.3% H 2 O 2 in methanol, the antigen was retrieved by microwave irradiation for 30 min. Immunoreaction with an anti-SSTR 2A antibody (rabbit, polyclonal, diluted 1 : 500 in 1% bovine serum albumin (BSA)-PBS, Gramsch Laboratories, Schwabhausen, Germany) was carried out at 4°C overnight. A biotinylated antibody against rabbit immunoglobulin (IgG) (goat, diluted 1 : 300 in PBS, DAKO, Carpinteria, CA, U.S.A.) was applied as the secondary antibody for 30 min. Immunoreactions were developed with ABC method using Vectastain ABC kit, and visualized with DAB solution containing H 2 O 2 . Negative control studies included substituting normal serum for the primary antibody. 
gsp mutation in adenoma cells
Six μm paraffin sections were deparaffinized in xylene (three times for 5 min), and rehydrated through graded ethanol to water. They were immersed at 37°C overnight in 50 μl of PK buffer per section (PK: 0.04% proteinase K, 10 mM Tris-HCL pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Tween 20), and genomic DNA was eluted in PK buffer. The DNA solution was centrifuged at 12,000 rpm at room temperature for 5 min, and the supernatant was collected. The DNA solution was heated at 95°C for 10 min and was applied to polymerase chain reaction (PCR), which was carried out using a PCR kit (Takara Taq, Takara Bio Inc., Otsu, Shiga, Japan) in 30 μl PCR mixture containing 250 μM dNTP mixture, 2 μl template, 0.3 μM F-primer, 0.3 μM R-primer, and 1 unit Takara Taq. Primer sets used for PCR of codon 201 were 5'-TGAGATCCATTGACCTCAATTTTGTT-3' and 5'-TTCCAGAGGGACTGGGGTGA-3', and additionally nested PCR was carried out using primer sets, 5'-TGTTTCAGGACCTGCTTCGC-3' and 5'-GGGTGAATGTCAAGAAACCATGAT-3'. Primer sets used for PCR of codon 227 were 5'-GCATG TTTGACGTGGGTGG-3' and 5'-AAAGCCAAGAG CGTGAGCA-3'. After a denaturing period of 2 min at 94°C, amplification was performed for 35 cycles at 94°C for 30 sec, 55°C for 40 sec, and 72°C for 45 sec using a DNA thermal cycler (Mastercycler, Eppendorf AG, Hamburg, Germany). After confirming the expected size of the PCR product by agarose gel electrophoresis, the PCR product was purified by a polyacrylamide gel electrophoresis. The band of interest was cut out from the polyacrylamide gel, precipitated by isopropanol, and directly sequenced using PRISM Ready Reaction Dye Deoxy Terminator Cycle Sequencing Kit and ABI 3100 PRISM sequencer (Applied Biosystems, Foster City, CA, U.S.A.).
Statistical Analyses
Statistical analyses were performed by Graphpad Prism (Graphpad Software, San Diego, CA, U.S.A.). The values are expressed as mean ± SD.
Results

Endocrinological data
The demographics of patients, basal endocrinological data, and responses to provocative tests are shown in Table 1 . The percentage ratio of nadir to basal GH by octreotide loading ranged from 1.31% to 78.22% (17.34 ± 15.18%). The percentage ratio of nadir to basal GH by oral administration of 2.5 mg bromocriptine ranged from 4% to 1105% (61 ± 155%). The percentage ratio of peak to basal GH by GHRH provocation ranged from 63% to 1836% (387 ± 417%).
Immunohistochemical examination
Results of immunohistochemical examinations of the adenomas are shown in Table 1 . All the adenomas from 56 acromegalic patients were GH-immunopositive, being confirmed to be somatotrophic. Ki-67 SI of the adenomas ranged from 0% to 3.50% (0.562 ± 0.743 %). All the adenomas examined were immunopositive for SSTR 2A. As mentioned above, according to the pattern of the immunohistochemical staining of SSTR 2A, all adenomas were classified into two groups: Group A (24 tumors) with weak and cytoplasmic-dominant staining of SSTR 2A (Fig. 1A) and Group B (32 tumors) with plasma membranedominant staining of SSTR 2A (Fig. 1B) .
gsp mutation of the adenoma cells Gsp mutation in codon 201 was observed in 21 of 56 adenomas (37.5%) and gsp mutation in codon 227 was observed in 5 of 56 adenomas (8.9%). The mutation in codon 201 was from Arg to Cys in 20 cases, and from Arg to His in 1 case. The mutation in codon 227 was from Gln to Leu in 5 cases. The prevalence of patients with gsp-positive adenomas was 46.4%, which was comparable to the prevalence (53%) reported for Japanese patients by Yasufuku-Takano et al. [10] .
The relationship among the acute effect of octreotide, immunohistochemical staining pattern of SSTR 2A and Ki-67 SI The percentage ratio of nadir to basal GH by octreotide loading of group A tumors with weak and cytoplasmic-dominant staining of SSTR 2A was 24.55 ± 17.68%, and that of group B tumors with plasma-membrane-dominant staining of SSTR 2A was 11.94 ± 10.33%, respectively. There was a statistically significant difference between group A and group B (unpaired t-test) (p = 0.0076).
There was no statistically significant difference in the mean Ki-67 SI between group A tumors and group B tumors (Mann-Whitney U test).
The percentage ratio of nadir to basal GH by octreotide loading was significantly associated with the proliferative potential of the adenomas demonstrated by Ki-67 SI (p = 0.021). The following correlation equation was derived by regression analysis (Fig. 2) . Y = 13.809 + 6.284 × X X = Ki-67 SI (%) Y = The percentage ratio of nadir to basal GH by octreotide loading (%) p = 0.021, r 2 = 0.094
The relationship among the effect of octreotide, gsp mutation and Ki-67 SI The mean percentage ratio of nadir to basal GH by octreotide loading in patients with tumors harboring gsp mutation was 13.76 ± 12.04%, and that in patients with tumors not harboring gsp mutation was 21.48 ± 17.49, respectively. The decrease of GH by octreotide loading was larger in adenomas with gsp mutation; however, it did not reach statistical significance (p = 0.057) (unpaired t-test). There was no statistically significant difference in the mean Ki-67 SI between patients with adenomas harboring gsp mutation and those with adenomas not harboring gsp mutation (Mann-Whitney U test).
The relationship between the SSTR 2A staining pattern and gsp mutation There was a statistically significant difference in the SSTR 2A staining pattern by gsp state (p = 0.0092) (Mann-Whitney U test). Adenomas with gsp mutation more likely displayed plasma-membrane-dominant staining of SSTR 2A.
The relationship among Ki-67 SI and other endocrinological data
The results of GHRH provocation test were available in 42 patients. There was no statistically significant correlation between Ki-67 SI and basal GH or IGF-1 level, between Ki-67 SI and the percentage ratio of nadir to basal GH by oral administration of 2.5 mg bromocriptine, or between basal GH or IGF-1 level and the percentage ratio of nadir to basal GH by bromocriptine or that of peak to basal GH by GHRH by regression analysis.
The relationship among gsp mutation and other endocrinological data
The mean percentage ratio of peak to basal GH by GHRH loading in patients with tumors harboring gsp mutation was 209 ± 179% and was 584 ± 512% in those with tumors not harboring gsp mutation, respectively. There was a statistically significant difference between the two groups (p = 0.003) (unpaired t-test). Adenomas with gsp mutation were less responsive to GHRH loading.
There was no statistically significant difference in the mean percentage ratio of nadir to basal GH by bromocriptine loading between patients with adenomas harboring gsp mutation and those with adenomas not harboring gsp mutation (unpaired t-test). There were no statistically significant differences in basal GH and IGF-1 between patients with adenomas harboring gsp mutation and those with adenomas not harboring gsp mutation (unpaired t-test).
The relationships among SSTR staining pattern and other endocrinological data
There was no statistically significant difference in the mean percentage ratio of peak to basal GH by GHRH loading between patients with adenomas of plasma-membrane-dominant staining of SSTR 2A and those with of cytoplasmic-dominant staining of SSTR 2A (unpaired t-test). There was no statistically significant difference in the mean percentage ratio of nadir to basal GH by bromocriptine loading between patients with adenomas of plasma-membrane-dominant staining of SSTR 2A and those with of cytoplasmic-dominant staining of SSTR 2A (unpaired t-test). There were no statistically significant differences in basal GH and IGF-1 between patients with adenomas of plasma-membrane-dominant staining of SSTR 2A and those with of cytoplasmic-dominant staining of SSTR 2A (unpaired t-test).
Multivariate analyses
Two factors were related to the acute effect of octreotide by monovariate analyses: plasma membranedominant staining of SSTR 2A and Ki-67 SI. The presence of gsp mutation had no relation with the acute effect of octreotide. Ki-67 SI and SSTR 2A staining pattern are independent factors to each other, and Ki-67 SI and gsp state are also independent to each other. Meanwhile, SSTR 2A staining pattern is significantly related with gsp state.
We subsequently assessed the contribution of these three factors on the acute effect of octreotide by multivariate analysis (Fig. 3) . The analyses revealed significant correlation between the acute effect of octreotide and the three factors (overall p = 0.003, r 2 = 0.029).
Post-tests revealed that the plasma-membranedominant immunostaining pattern of SSTR 2A correlated with the reduction of GH by octreotide (p = 0.009). However, the Ki-67 SI did not show significant correlation with the reduction of GH by octreotide (p = 0.134). The presence of gsp mutation had no correlation with the reduction of GH by octreotide (p = 0.278).
The following formula was produced to predict the acute effect of octreotide on GH secretion of somatotroph adenomas (Fig. 4) . 
Discussion
We found two major factors, plasma-membranedominant immunostaining pattern of SSTR 2A and Ki-67 SI, influenced the acute effect of octreotide in pituitary somatotroph adenoma, when monovariate analyses (Pearson's product-moment coefficient) were used. Gsp mutation had no significant relation with the acute effect of octreotide in our series.
These three factors, immunostaining pattern of SSTR 2A, Ki-67 SI and gsp state, contributed differently to the acute effect of octreotide when analyzed by multivariate analysis (p = 0.003). Post-tests revealed that the plasma-membrane-dominant immunostaining pattern of SSTR 2A was significantly related to the acute effect of octreotide (p = 0.009). Although monovariate regression analysis revealed the inverse relation of Ki-67 SI to the acute effect of octreotide, post-test did not confirm the significant inverse relationship. Additionally, we found that there was a significant relation between the presence of gsp mutation and the GH response to GHRH loading test. Serum GH in patients with gsp mutation was less responsive to GHRH. This relationship was also consistent with a previous report [10] .
We also found that the result of GHRH provocation test showed significant inverse correlation with Ki-67 SI; that is, tumors that respond stronger to GHRH exhibited lower proliferation index. It could be interpreted to mean that tumors that are less responsive to GHRH are more dedifferentiated, hence such tumors have higher proliferative potentials.
Kontogeorgos stated that both the presence and subcellular localization of somatostatin receptor is important in assessing pituitary adenomas, because its density in the cytoplasmic membrane is directly related to the effectiveness of treatment with somatostatin analogues [1] . Takei et al. also reported that adenomas with plasma membrane-dominant staining of SSTR 2A (more than 50% of membrane-positive tumor cells) had a significant correlation with percent decrease of GH after octreotide loading [2] . The present study is consistent with their results. Because functional SSTR resides in the cell membrane, it is suggested that cytoplasmic SSTR has low biological activity.
Ki-67 SI is a major prognostic indicator for pituitary adenomas in the recent WHO classification of pituitary adenomas, in which adenomas with Ki-67 SI more than 3% are classified as atypical adenomas [11] . Thapar et al. found that Ki-67 SI was low in noninvasive adenomas, more than 3-fold higher in adenomas with gross invasion than in noninvasive adenomas, and that Ki-67 SI reached as high as 12% in pituitary carcinomas [12] . The breakpoint in Ki-67 SI concerning invasiveness appeared to be 3%, with 72.7% sensitivity and 97.3% specificity. In the present study, we found another importance of Ki-67 SI: Ki-67 SI is inversely related to the effectiveness of octreotide treatment.
Somatostatin analogues such as octreotide are also used in the medical treatment in pancreatic neuroendocrine tumors. Aparicio et al. evaluated the anti-tumor efficacy of somatostatin analogues in 35 consecutive patients with documented progressive neuroendocrine tumors [13] . They found that a slow tumor growth rate before treatment was predictive of a good response to somatostatin analogues [13] . Their finding in neuroendocrine tumors is consistent with our results that a low Ki-67 SI correlates with the effectiveness of octreotide treatment.
There are several papers showing that tumors harboring gsp oncogene are sensitive to somatostatin analogues. However, this was not reproduced in our series or in a previous paper [10] which analyzed the data for 100 Japanese patients. In the other papers [6, 7, 9, 14] , acute administration as well as chronic treatment with octreotide caused a reduction of serum GH levels that was prominent in patients with gsp-positive tumors. These results are consistent with in vitro studies showing increased sensitivity to somatostatin analogues in cells obtained from tumors with gsp oncogene [9, 15] . A cAMP-responsive element is present in the promoter region of SSTR 2 gene, suggesting that the constitutive activation of adenylyl cyclase by gsp mutation might result in increased SSTR 2 expression and therefore increased sensitivity to octreotide that preferentially binds to SSTR 2 [16] , although there is no evidence for a relationship between gsp mutation and SSTR 2 mRNA induction [17, 18] In our study, there was statistically significant difference in the SSTR 2A staining pattern by gsp state. Adenomas with gsp mutation more likely displayed plasma-membrane-dominant staining of SSTR 2A. This may represent the above mentioned increase of SSTR 2 expression, caused by the constitutive activation of adenylyl cyclase by gsp mutation, which result in membrane dominancy of SSTR 2A.
Barlier et al. reported that the diminished sensitivity to octreotide might represent one step in the dedifferentiation drift [17] . Adenomas with gsp mutation have increased SSTR expression and are more sensitive to octreotide treatment, whereas adenomas without gsp mutation have smaller amounts of SSTR and are less sensitive to octreotide. Decreased sensitivity to octreotide may represent one step to dedifferentiation and have more proliferative potentials. However, in the present study, there was no significant difference in Ki-67 SI between adenomas with or without gsp mutation. One explanation for the lack of difference in Ki-67 SI may derive from the fact that high expression of Gsα protein in some adenomas without gsp mutation constitutively stimulates the cAMP-PKA pathway. Bertherat et al. showed that, in GH-secreting adenoma cells, high levels of wild-type Gsα protein expression promotes cAMP response element (CRE)-binding protein phosphorylation [19] . Over-expression of the wild Gsα protein or the expression of the mutated gsp protein is both able to induce activation of cAMP pathway in the HEK 293 cell line [20] . The increased expression of Gsα protein in some adenomas without gsp mutation could also have a strong impact as the mutation itself [21] . These findings may explain why the existence of gsp mutation had little if any impact on the acute octreotide effect and no relation with Ki-67 SI. In fact, studies using large series of somatotroph adenomas indicate the absence of differences in other aspects such as tumor growth and recurrence between patients with adenomas with and without gsp mutation [6, 14, 16, 18] .
In conclusion, three factors, the immunostaining pattern of SSTR 2A, Ki-67 SI and gsp mutation, contributed differently to the acute effect of octreotide (p = 0.003). Post-tests revealed that the plasmamembrane-dominant immunostaining pattern of SSTR 2A was significantly related to the acute effect of octreotide (p = 0.009).
